Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP and Hyaluronic Acid for Traumatic Olfactory Dysfunction
NCT06290219Phase 3Not yet recruiting
- Sponsor
- Taichung Veterans General Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Polymer-based Nanoparticles, Adipose-derived MSCs, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of platelet-rich plasma and hyaluronic acid in Olfactory nerve injury, sponsored by Taichung Veterans General Hospital. Primary endpoint: phenyl ethyl alcohol odor detection threshold at 12 weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
platelet-rich plasmahyaluronic acid
03
Conditions
Olfactory nerve injury
Beyond the preview
Go deeper on NCT06290219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290219.